Aptorum Group Limited (NASDAQ:APM) Short Interest Up 232.3% in February

Aptorum Group Limited (NASDAQ:APM) was the target of a large growth in short interest in February. As of February 13th, there was short interest totaling 10,060 shares, a growth of 232.3% from the January 29th total of 3,027 shares. Based on an average daily trading volume, of 77,267 shares, the short-interest ratio is presently 0.1 days. Currently, 0.4% of the company’s stock are sold short. Currently, 0.4% of the company’s stock are sold short. Based on an average daily trading volume, of 77,267 shares, the short-interest ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Aptorum Group in a research note on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Aptorum Group Stock Down 2.6%

Shares of NASDAQ APM opened at $0.79 on Thursday. Aptorum Group has a fifty-two week low of $0.65 and a fifty-two week high of $4.47. The firm’s 50-day simple moving average is $0.96 and its 200 day simple moving average is $1.42.

About Aptorum Group

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.